News | September 11, 2008

St. Jude Medical Receives FDA Clearance of Implantable Device to Monitor Cardiac Conditions

September 12, 2008 - St. Jude Medical Inc. yesterday said the FDA cleared its SJM Confirm implantable cardiac monitor (ICM), a compact device designed to help physicians diagnose abnormal heart rhythms.

The implantable monitor enables physicians to evaluate heart rhythm signals over a longer period of time than allowed by standard monitoring tests, and is designed to help them diagnose and document difficult-to-detect rhythm disorders in patients who may suffer from unexplained symptoms, including syncope (the sudden and transient loss of consciousness), palpitations and shortness of breath.

About the size of a computer thumb drive, the SJM Confirm ICM is said to be the smallest implantable cardiac monitor available. It is implanted just under the skin (subcutaneously) in the upper chest region and can be implanted in an outpatient procedure under local anesthesia. Patients are able to remotely send data to their physicians when they experience symptoms. This real-time data helps physicians diagnose and treat the arrhythmias.

The SJM Confirm ICM features a St. Jude Medical sensing algorithm designed to enhance signal detection, enabling physicians to program the device to be more sensitive to small and wide-ranging signals. Electrodes on the monitor sense cardiac activity and a continuous loop recorder stores information about the heart's activity. The electrodes are positioned on opposite sides of the device, which is intended to provide better contact with the subcutaneous tissue for more accurate sensing of cardiac signals, the company said.

Syncope is responsible for about 3 percent of all emergency room visits and up to 6 percent of all hospitalizations. About 1 million people in the U.S. suffer from syncope, and the source of unexplained syncope, according to some physicians, is the most difficult diagnosis to make. Even after a physical examination and electrocardiogram (ECG) evaluation through a Holter monitor, about half of all cases of unexplained syncope go undiagnosed.

The SJM Confirm ICM is the first implantable monitor to be built on a unified platform, which has enabled St. Jude Medical to more quickly introduce devices with new features and diagnostics (as they become available) because the basic platform for all of the devices is the same. The St. Jude Medical Unity device platform first was introduced in September 2007 with the launch of its Promote RF CRT-D and the Current RF ICD devices. Due to its uniform software interfaces and expanded features, the new platform gives physicians more choices during device programming and patient follow-up, the company said.

The SJM Confirm ICM also features programmable event triggers, which enable physicians to program the device to automatically capture and record up to 60 seconds before and after a cardiac event. The device has a three-year life span. It is compatible with the St. Jude Medical Merlin Patient Care System, a portable computer designed to help physicians access and analyze diagnostic information and print full-size comprehensive data reports. It also allows remote monitoring so patients can send data directly to their physicians.

The SJM Confirm ICM will be launched in October 2008, the company said.

For more information: www.sjm.com

Related Content

HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function
News | ECG | April 27, 2018
HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG | January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG | October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG | November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG | October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG | September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
Overlay Init